Business Wire

UN Migration Agency Selects Kony to Accelerate Digital Strategy to Reach More Migrants

Del

Kony, Inc., a leading enterprise mobility and digital applications company, announced that it has been selected by IOM, the UN Migration Agency, to accelerate its digital strategy and support its vision to provide information and humanitarian services to more migrants and government agencies.

As the world’s leading intergovernmental agency dedicated to the wellbeing, safety and engagement of migrants, IOM will use the Kony AppPlatform to deliver mobile apps, including the MigApp, to provide key information and humanitarian services to migrants worldwide.

IOM works closely with governmental, intergovernmental and non-governmental partners. With 166 member states, over 400 field locations and more than 90 per cent of its staff deployed in the field, mobile applications play a critical role in the success of IOM as one of the lead responders to the world’s worst humanitarian emergencies.

IOM is dedicated to enabling humane and orderly migration, promoting international cooperation on migration, assisting in the development of practical solutions for migration issues and providing humanitarian assistance to migrants, including refugees and internally displaced persons.

Many migrants encounter tremendous challenges throughout their journeys and though many migrants, especially those forcibly displaced or migrating irregularly, carry very few personal possessions, most people do carry a smartphone, which can be a gateway to reliable and practical information on migration and humanitarian services.

IOM intends to use the Kony AppPlatform to build multiple apps to support its mission, not only to empower migrants to take charge of their own journey, but also reduce their dependency on unauthorized entities and processes that are not beneficial to the migrants.

“Since our establishment in 1951, IOM upholds the belief that migration builds resilience,” said Bernardo Mariano, IOM’s Director of the Information and Communication Technology Division. “Migrants are agents of change and development. Our ultimate objective is to reduce the human and financial costs of migration through increased engagement with migrants. We look forward to leveraging Kony’s technology, expertise and secure mobile applications to further our commitment to the principle that humane and orderly migration benefits not just migrants but all of society,” he added.

IOM selected the Kony platform to develop and deliver the MigApp, with the goal of reaching 1 billion migrants and achieving 1 million downloads of the app by 2018. The MigApp is a one-stop-shop application that users can download to their mobile phones for free to access information and services relevant to their migration process.

The goal is to help migrants make informed decisions, provide them with access to services related to their migration process, and allow access to IOM programmes. Features planned for the first phase of MigApp include:

  • Remittance comparison allowing migrants to find cost-effective ways to send money home;
  • Access to up-to-date practical information on IOM programmes and services;
  • “I am a Migrant” space where migrants can share their experiences, tell their stories and upload photos to share with other MigApp users;
  • Notification services providing alerts on emergencies, health-care information, and other important information related to their location;
  • IOM news;
  • Online registration enabling IOM to capture data which can be used to analyse migration patterns and trends.

“We are thrilled to partner with all global leaders, and we take special pride in supporting the mission of the UN Migration Agency,” said Thomas E. Hogan, Chairman and Chief Executive Officer, Kony, Inc. “As a global citizen deeply committed to the communities we serve, our contribution to humanitarian services for the world’s migrants is both important and rewarding.”

For more information, please visit www.kony.com. Connect with Kony on TwitterFacebook, and LinkedIn.

Contact information

IOM
Alex Dougan, + 41 22 7179 352
adougan@iom.int
or
Kony, Inc.
Jean Kondo +1 510-823-4728
Jean.kondo@kony.com
or
Blanc & Otus
Danielle Tarp +1 415-856-5182
Danielle.tarp@blancandotus.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00Pressemelding

Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im

CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00Pressemelding

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates

Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26Pressemelding

Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a

General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05Pressemelding

General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges

Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03Pressemelding

Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o

Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00Pressemelding

Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and